Tag: David Wohl

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

As Fischer and Wohl Fight Disease in Sub-Saharan Africa, the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR) Selects UNC to be a Regional Emerging Special Pathogen Treatment Center (RESPTC). Read press announcement. Many courageous infectious disease specialists and other clinicians have not shied...

Survivors of the Ebola outbreak in 2014 report a wide range of lingering symptoms that include fatigue and muscle pain, as well as neurological issues. But not much has been known about the persistence and severity of the symptoms over time. Investigators from the Institute for Global Health & Infectious...

COVID-19 has become a leading cause of death and reduced life expectancy in the U.S., especially among Black and Latino populations. David Wohl, MD, member of the Institute for Global Health & Infectious Diseases and professor of medicine in infectious diseases, and first author Jessie Edwards, PhD, assistant professor in the...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and...

Presented by David Wohl, MD, professor of medicine, UNC Division of Infectious Diseases Wohl is site leader of UNC’s Global Infectious Diseases Clinical Research Group at Chapel Hill. For the past year, during the COVID-19 pandemic, Wohl has been serving as medical director of the COVID-19 vaccination clinics at UNC...

  A team of investigators from UNC’s Institute for Global Health and Infectious Diseases has been awarded $1.5 million from the National Institutes of Health to conduct a two-year implementation science study to scale up COVID-19 testing in North Carolina. The researchers will examine the impact of a COVID screening...

ACTG names second new award for former UNC neurology professor, Kevin Robertson The national AIDS Clinical Trials Group expanded its annual recognition program in 2020 with two new awards named for University of North Carolina faculty members who died in 2019: Charles van der Horst, MD, an infectious diseases physician...

  Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19,...

  UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute...

  It’s hot (especially wearing full PPE), it’s tedious, and it’s critical. A volunteer team of UNC infectious diseases faculty members along with UNC hospitalists has been conducting drive-up testing for COVID-19 in Sanford, NC, about 35 miles south of Chapel Hill, twice a month since June, seeing roughly 1,000...